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Abstract: Human neurodegenerative diseases are devastating illnesses that predominantly affect elderly people. The majority of the 
diseases are associated with pathogenic oligomers from misfolded proteins, eventually causing the formation of aggregates and the 
progressive loss of neurons in the brain and nervous system. Several of these proteinopathies are sporadic and the cause of pathogenesis 
remains elusive. Heritable forms are associated with genetic defects, suggesting that the affected protein is causally related to disease 
formation and/or progression. The limitations of human genetics, however, make it necessary to use model systems to analyse affected 
genes and pathways in more detail. During the last two decades, research using the genetically amenable fruitfly has established 
Drosophila melanogaster as a valuable model system in the study of human neurodegeneration. These studies offer reliable models for 
Alzheimer’s, Parkinson’s, and motor neuron diseases, as well as models for trinucleotide repeat expansion diseases, including ataxias and 
Huntington’s disease. As a result of these studies, several signalling pathways including phosphatidylinositol 3-kinase (PI3K)/Akt and 
target of rapamycin (TOR), c-Jun N-terminal kinase (JNK) and bone morphogenetic protein (BMP) signalling, have been shown to be de-
regulated in models of proteinopathies, suggesting that two or more initiating events may trigger disease formation in an age-related 
manner. Moreover, these studies also demonstrate that the fruitfly can be used to screen chemical compounds for their potential to 
prevent or ameliorate the disease, which in turn can directly guide clinical research and the development of novel therapeutic strategies 
for the treatment of human neurodegenerative diseases. 
Keywords: Alzheimer’s disease, Parkinson’s disease, motor neuron disease, trinucleotide repeat expansion disease, c-Jun N-terminal kinase, 
bone morphogenetic protein, neurodegeneration, Drosophila. 
INTRODUCTION 
  Human neurodegenerative diseases describe a clinical condition 
characterised by the selective and progressive loss of neurons, 
eventually leading to cognitive, behavioural and physical defects 
that can cause the death of the patient [1]. Neurodegenerative 
diseases are categorised by clinical appearance and pathology, such 
as movement disorders (e.g. Parkinson’s (PD), Huntington’s (HD), 
motor neuron diseases (MND)) and dementias (e.g. Alzheimer’s 
disease (AD), fronto-temporal dementia (FTD)); by the type(s) of 
neurons affected, such as dopaminergic (PD), GABAergic (HD) or 
motor neurons (MND); and by means of origin as to whether the 
form of disease is heritable (familial cases) or not (sporadic cases). 
Age is the greatest risk factor and adult-onset neurodegenerative 
diseases present a growing socio-economic burden for developed 
societies because of increased life expectancy. Current estimates for 
the number of individuals suffering, for example, from AD are as 
high as 16 million across the United States, France, Germany, Italy, 
Spain, United Kingdom, and Japan, and the prevalence of AD is 
estimated to exceed 21 million patients by 2010 [2]. 
  For the vast majority of neurodegenerative diseases, the causes 
are unclear and effective treatments are lacking. At its best, 
prescribed treatments such as acetylcholinesterase inhibitors (AD 
treatment) [3] or levodopa (PD treatment) [4] provide modest 
symptomatic relief in a proportion of patients. To date, no drug has 
been identified that does more than improve symptoms. This is 
particularly exigent for those 95% of patients that suffer from a 
sporadic form of disease. In those sporadic cases, no indication 
allows a decided inference about the underlying causes as well as 
the pathogenic mechanisms involved, apart from age as the main 
risk factor. This lack of mechanistic insights has been challenged 
over the last two decades by two different but mutually overlapping 
approaches. 
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  The first approach addresses the nature and content of 
proteinaceous inclusions that are typical pathological features of the 
majority of neurodegenerative diseases, including AD, PD, FTD, 
several trinucleotide repeat expansion diseases (TRED) and MND. 
These inclusions are characterised by protein aggregates that 
accumulate in the extracellular milieu or intracellular compartments 
of affected neurons. The proteins are usually modified (fragmented, 
phosphorylated, ubiquitinated) and their identification provides a 
mechanistic link to the potential aberrant pathway mediating 
pathogenesis. Textbook examples are amyloid plaques in AD that 
comprise fragments of aberrantly cleaved amyloid precursor protein 
(APP) [5-8], Lewy bodies in PD that comprise forms of alpha-
synuclein (ASYN) [9], tangles in AD, FTD, PD and MND that 
comprise forms of tau [10-14], and more recently TAR DNA 
binding protein 43 (TDP-43) containing aggregates in MND, FTD, 
AD and PD [15, 16]. It is a striking mystery, however, that 
comparable inclusions can be observed in several diseases, such as 
tangles in AD and MND, although present in different neuronal cell 
types. This enigma as well as clinical evidence suggesting that 
neurodegeneration can occur even in the absence of inclusion 
formation continues to fuel the debate as to whether aggregate 
formation is a cause of disease or rather an attempt of the cell to 
protect itself. In any case, the identification of the nature and 
content of proteinaceous inclusions alone has not revealed a major 
breakthrough in understanding disease formation. However, in 
conjunction with information generated by the second approach, 
these data led to the identification of key pathogenic pathways 
operant in human neurodegeneration. 
  The second approach addresses familial forms of neurodegene-
rative diseases, even though they represent only the minority of 
about 5% of all cases. Familial cases show clinical features similar 
to sporadic cases but at the same time are heritable, substantiating 
the reasonable quest to identify the origin, cause and underlying 
mechanisms of disease. Accordingly, large-scale pedigree analyses 
and genome-wide association studies have been and are still carried 
out in order to identify genes and loci that are affected in 
neurodegenerative diseases [see recent example, 17, 18]. These 
efforts led to the identification of APP, tau, ASYN, Huntingtin 
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HD, and MND, respectively. The genetic data corroborate earlier 
observations that proteinaceous inclusions harbour Abeta fragments 
derived from aberrant APP cleavage (amyloid plaques), tau 
(tangles), ASYN (Lewy bodies), polyglutamine expanded HTT and 
TDP-43. The fact that inclusion content and a mutant allele 
converge on the same defective protein unifies familial and 
sporadic cases and strongly suggests that the affected protein is 
causally related to disease formation and/or progression. 
  The limitations of human genetic studies however, often make 
it difficult to analyse genes and pathways in any further detail, 
because of complex patterns of inheritance, lack of sufficient family 
pedigree data and population-based genetic heterogeneity. 
Therefore, model systems are used to study specific functional 
aspects of the genes/proteins identified in neurodegenerative 
diseases. These models range from yeast [19] and C. elegans [20] to 
mammals and human cell culture systems. But yet, in most of the 
cases, these models fulfil only some of the criteria expected to 
apply in the study of human neurodegeneration. Essential criteria 
include: cognitive, behavioural and physical dysfunction caused by 
cell type-specific neurodegeneration; cellular pathophysiology 
including aggregate formation; clear pattern of inheritance; 
pedigree data covering three and more generations; population-
based genetic homogeneity. In addition, an ideal model system 
would provide further detailed information: case-specific data 
spanning a whole life from conception to age-related death, which 
would allow the study of disease formation and progression in 
relation to age as the major risk factor; knowledge about the focus 
of disease, its time and site of origin, which in turn would allow the 
visualisation and eventually manipulation of disease formation and 
progression; and large numbers of genetically identical individuals, 
like multiple twins, that would allow strong power calculations to 
deduce quantitative traits as well as insights into pathogenic 
mechanisms in a statistically significant manner. An organism that 
meets all these criteria in a formidable way is the fruitfly 
Drosophila melanogaster. 
DROSOPHILA MELANOGASTER 
 The protostomian, ecdysozoan arthropod Drosophila 
melanogaster belongs to a sub-species of the Drosophilidae, 
dipteran insects that are found all over the globe. During the course 
of evolution, the arthropod lineage already separated from the 
vertebrate lineage more than 600 million years ago [21, 22], 
suggesting that Drosophila might be completely unrelated to 
humans. However, genetic, molecular and behavioural analyses 
over more than a century suggest otherwise, and Drosophila has 
been used as a prime model organism for experimental studies of 
multi-cellular eukaryotic biology. This led to the discovery of 
fundamental biological principles, such as validation of the 
chromosomal theory of inheritance and the first experimental 
description of the gene as a functional unit [23]. 
  Apart from tradition, the reasons for using the fruitfly as a study 
object are manifold: Drosophila is cheap and easy to maintain in 
the laboratory (Fig. 1a); it can give rise to a large number of 
genetically identical progeny; it has a rather short life span ranging 
from 40 to 120 days (Fig. 1b) depending on diet and stress [24, 25]; 
it shows complex behaviour, including learning and memory [26, 
27], driven by a sophisticated brain (Fig. 2) and nervous system 
[28]. The entire Drosophila genome is encoded by roughly 13,600 
genes as compared to 27,000 human genes, located on only four 
pairs of chromosomes as compared to 23 pairs in human [29]. 
Thanks to very well-described anatomy and development [30, 31], 
and the availability of molecular genetic tools [32-34], Drosophila 
is one of the most extensively used genetic model organisms to 
study complex biological processes. In comparison to other 
organisms like C. elegans and the mouse, the fly provides a very 
powerful genetic model system for the analysis of brain and 
behavioural disorders related to human disease: its brain is complex 
enough (as compared to C. elegans) to make fly behaviour highly 
interesting and relevant to humans but it is still small enough (as 
compared to mouse) for an in-depth structural and functional 
analysis [35]. 
  The value of Drosophila as a model system has been amply 
demonstrated by the fact that many genes and processes first 
discovered in the fly have proven to be conserved in other 
organisms, including humans. Comparative analysis of whole 
genome sequencing revealed striking similarities in the structural 
composition of individual genes of Homo sapiens and Drosophila 
[36]. Moreover, the molecules and mechanisms underlying core 
modules of cell biology are conserved as well: homologous genes 
mediate homologous pathways such as cyclin/cdk modules 
regulating the eukaryotic cell cycle [37-39], or insulin signalling 
regulating metazoan cell growth [40, 41]. These data provide 
compelling evidence for the structural conservation of genes due to 
common origin; they elucidate a deep homology underlying cell 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Drosophila as a model organism in the study of age-related neurodegeneration. (a) The arthropod Drosophila melanogaster belongs to a sub-
species of the Drosophilidae, dipteran insects that fit on a pencil tip and can be easily kept en masse in the laboratory. Their anatomy displays characteristic 
features such as compound eyes, wings and bristles that can be used as phenotypes to study neurodegeneration without affecting the survival of the fly. (b) The 
lifespan of Drosophila depends on diet and stress and varies between 40-120 days. The more rigid a diet (e.g. cornmeal), the longer a fly can live, whereas 
increase in carbohydrates and cholesterol (e.g. 15% sugar/yeast) can lower life expectancy. These similarities to human ageing and lifespan, together with a 
highly conserved genetic makeup, make Drosophila a powerful model system in the study of adult-onset, age-related neurodegeneration. 506      CNS & Neurological Disorders - Drug Targets, 2010, Vol. 9, No. 4  Frank Hirth 
biological mechanisms that extends beyond gene structure to 
patterned protein expression and function. This notion is further 
supported by experiments demonstrating that Drosophila and 
human genes can substitute each other in species-specific but 
evolutionarily conserved mechanisms underlying brain 
development in insects and mammals [42-45]. 
  Based on these observations, it is obvious that Drosophila can 
offer unique opportunities in the study of human 
neurodegeneration: Most of the genes implicated in familial forms 
of disease have at least one fly homolog [46] (see Tables 1-4); 
fundamental cellular processes related to neurobiology are similar 
in Drosophila and humans, including synapse formation, neuronal 
communication, membrane trafficking and cell death; the 
neurobiological bases of behaviour are of the same kind in flies and 
humans, including sensory perception, integration and motor 
output, as well as aspects of learning and memory formation. These 
features make Drosophila a prime model organism in the study of 
adult-onset, age-related neurodegeneration. 
DROSOPHILA IN THE STUDY OF NEURODEGENERATION 
  The fundamental aims in the study of neurodegeneration are to 
elucidate underlying pathogenic pathway(s) and in turn the 
development and successful application of targeted treatment(s) to 
stop or at least ameliorate the disease. The genetic dissection of 
disease pathways is therefore a reasonable means to address these 
aims and three mutually interrelated approaches are utilised in 
Drosophila: 
 
(i)  mis-expression of a human disease gene, in its wild-type or 
mutant form; 
(ii)  loss and gain of function of the Drosophila homolog of a 
human disease gene; 
(iii)  genetic screens to identify enhancers and suppressors that 
are able to modify a phenotype caused by (i) and (ii). 
  Mis-expression of a human gene is used to  investigate its 
functional properties in a neurodegenerative process and to 
elucidate its interactions with other Drosophila proteins. This is 
usually achieved by using the Gal4/ upstream activating sequence 
(UAS) system that allows time- and tissue-specific mis-expression 
of any gene of interest in Drosophila [47]. Most robust models have 
been established using nervous system-specific Gal4 drivers, 
thereby corresponding to the human condition. However, several 
other tissues are also used as a phenotypic read-out system, 
including the compound eyes, wings and bristles, because a 
degenerative phenotype can be revealed without affecting the 
survival of the fly. Especially the compound eye is predominantly 
used because it allows the generation of a neurodegenerative 
phenotype (rough eye phenotype) that can be easily scored under a 
standard light microscope [see, for example, 48], and in turn can be 
utilised for genetic enhancer/suppressor screens. 
  There are, however, serious drawbacks to this approach: (i) 
degeneration can occur by excess Gal4 protein itself [49], thereby 
causing a rough eye phenotype unrelated to the disease gene under 
investigation; (ii) a rough eye phenotype can occur by degeneration 
of accessory cells unrelated to neurodegeneration; (iii) the severity 
of a degenerative phenotype may not relate to the amount of protein 
expressed because of the way the UAS construct (harbouring the 
human disease gene) has been integrated into the fly genome 
(position effect). The latter can and should be avoided by site-
specific genomic integration of the UAS construct (for details, see 
[50]) so that the same levels of protein expression are achieved. In 
comparison to wild-type protein expression, only this will permit 
meaningful conclusions about the impact of mis-expressing a 
human mutant protein or its post-translational modifications that 
frequently occur in neurodegeneration, such as hyper-
phosphorylation or ubiquitination. 
  The second approach applies standard analytical techniques 
available to study the function of a Drosophila gene/protein. These 
include mutational inactivation for a loss-of-function analysis, and 
Gal4/UAS-mediated RNA interference for a knockdown or over-
expression for gain-of-function analyses, with several modifications 
and more sophisticated possibilities available [28, 51-55]. The 
ultimate goal is to gain insights into the role and function of a 
Drosophila homologue of a human disease gene. By way of 
homology between the fly and human protein, a reasonable 
inference can be made on the function of the human protein, and 
hypotheses and predictions can be deduced about the potential 
pathogenic pathway(s). Following this approach, it has been shown 
first in Drosophila that mitochondrial dysfunction can result from 
defective PINK1/Parkin signalling which appears to be one of the 
pathogenic pathways underlying PD [56-58]. 
  A third approach is utilised once a neurodegenerative 
phenotype is established. Drosophila offers the advantage of 
performing unbiased genetic screens to identify enhancers and 
suppressors on a genome-wide basis. Several labs have used the 
ease and accessibility of the compound eye to carry out such 
modifier screens, and targeted genes that either suppress or enhance 
the rough eye phenotype, thereby signifiyng the candidate genes as 
members of a common pathogenic pathway. These attempts have 
 
 
 
 
 
 
 
 
Fig. (2). Adult brain of Drosophila. (a) Confocal image of a parafin cross-section through the adult Drosophila head; auto-immunofluorescence visualises the 
ommatidia of the compound eye (CE), the optic lobe (OL) and the central brain (CB). Note that cell bodies (arrowheads) are topologically separated from 
axonal extensions which make up the neuropil. (b) Confocal image of a whole mount adult brain immunolabelled with anti-nc82 which recognises the 
Bruchpilot protein that is specifically enriched in active zones of synaptic terminals. This allows the visualisation of cortical areas in the fly brain, including 
optic lobes (OL), antennal lobes (AL), superior protocerebrum (SP), lateral protocerebrum (LP), mushroom bodies (MB), deuterocerebrum (D), and 
subesophageal ganglion (SG). (c) Optical cross-section of a whole-mount adult brain of a transgenic Drosophila immunolabeled with anti-nc82; tyrosine 
hydroxylase (TH)-specific Gal4 drives UAS-mCD8:GFP expression, a membrane-tagged GFP (TH>mGFP). Because TH is the rate-limiting enzyme of 
dopamine synthesis, this transgenic Gal4/UAS combination visualises dopaminergic neurons and their axonal extensions (white/light grey). Based on this 
method, dopaminergic neurons can not only be monitored, but also manipulated, and cell numbers as well as axonal projections can be used as phenotypic 
read-out parameters to study parkinsonism in Drosophila. Scale bar: 50 μm. Drosophila melanogaster in the Study of Human Neurodegeneration  CNS & Neurological Disorders - Drug Targets, 2010, Vol. 9, No. 4     507 
identified several ‘key’ interacting partners of tau, Abeta and 
ASYN [59-65]. However, in only very few cases [62, 66], the 
results obtained in Drosophila led to the identification of a human 
homologue that is similarly involved in the corresponding human 
disease. The potential reason(s) for such a meagre yield are 
phenotypic screens predominantly based on eye-specific Gal4 
drivers that are already active during development, thereby 
generating a rough eye phenotype in the newly hatched adult fly - a 
situation that does not mimic nor model adult-onset 
neurodegeneration in an age-related manner. 
  In addition to these genetic approaches, a fourth one uses 
established fly models of neurodegeneration in order to screen 
compound collections for their potential to prevent or ameliorate 
the “disease”. A Drosophila compound screen is achieved by 
simply feeding flies with their usual food to which a defined 
concentration of the compound has been added (Fig. 3). There are 
obvious drawbacks to such screens, especially when used for adult 
onset, age-related neurodegeneration phenotypes, as these screens 
are time-consuming and far from being “high-throughput”. In 
addition, compound screens have been ineffective when based on a 
rough eye phenotype that is generated during development and 
detectable in the newly hatched adult fly [Luz and Hirth, 
unpublished]. This is because flies can be easily raised on drug-
treated food but ingestion stops during puparium formation and the 
subsequent pupal stage, which lasts four days until the adult fly 
hatches. Moreover, this final stage of development is characterised 
by a high metabolic rate related to metamorphosis, during which a 
previously incorporated drug loses its efficacy. 
  Despite all these limitations, Drosophila has been used 
successfully to identify compounds that not only improve 
symptoms, but also modify the course of the “disease”. These 
successful cases are mainly (but not only) based on fly models of 
adult-onset, age-related neurodegeneration, and resulted in 
improvements relevant to human disease, including extended life-
span in models of AD [67] and prolonged survival of dopaminergic 
neurons in models of PD [68, 69] as well as the complete rescue of 
disease-related phenotypes [70]. The relevance and impact of such 
small-scale compound screens in Drosophila cannot be rated highly 
enough because of their potential for translational research: the 
fruitfly is a complex behaving animal with a sophisticated, 
centralised nervous system including a blood-brain barrier [71], and 
therefore superior to cell cultures and C. elegans, but still 
inexpensive and short-lived as compared to mice. Accordingly, 
Drosophila drug screens in cancer research [72] have already 
identified compounds that are now in phase I and II clinical trials, 
illustrating the enormous potential for its application in the study of 
human diseases. 
  The above mentioned experimental approaches have established 
Drosophila as an excellent model organism in the study of human 
neurodegeneration. Numerous reviews have covered detailed 
aspects of this topic and are highly recommended to the reader [73-
85]. In the following article, key and novel findings as well as their 
implications are summarized and reviewed. A special emphasis is 
given to Drosophila models of AD, PD, TREDs and MNDs. 
ALZHEIMER’S DISEASE 
  Alzheimer’s disease is the most common neurodegenerative 
disease affecting primarily elderly people. Over 95% of the known 
cases are sporadic, whereas less than 5% account for familial cases 
[86, 87]. These heritable cases led to the identification of genes 
that, when mutated appear to be involved in AD pathogenesis, 
including APP, presenilins 1 and 2 (PSN-1/2) and tau (Table 1). In 
addition, Apolipoprotein E isoform epsilon4 has been identified as 
a risk factor [88]. AD is characterized by progressive memory loss 
and the subsequent degeneration of large areas of the brain [89, 90]. 
Microscopically, AD pathology reveals neuritic plaques, composed 
mainly of Abeta peptides, and neurofibrillary tangles, composed of 
abnormal tau protein [86, 91, 92]. Abeta peptides are produced by 
proteolytic cleavage of the APP transmembrane receptor at the beta 
and gamma sites. Familial mutations (familial AD, FAD) in APP 
result in increased production of Abeta42 peptide, the 
amyloidogenic form of the two Abeta species, Abeta40 and 
Abeta42. Abeta42 forms protofibrils and fibrils much more readily 
than Abeta40 and is the predominant form of the peptide found in 
plaques. The membrane-tethered aspartyl protease beta-site APP-
cleaving enzyme (BACE) cleaves APP at the beta site, and the 
presenilins, PS1 and PS2, participate in APP cleavage at the gamma 
site along with the genes nicastrin, Aph-1 and Pen-2. These data led 
to the amyloid cascade hypothesis as the main culprit of AD 
formation [93, 94]. Drosophila carries homologues of AD-related 
genes, including APP, presenilin, and tau (Table 1), which has 
made it a model system in AD research. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Drug treatment in Drosophila. (a)  Four vials with flies are kept on cornmeal food each of which has been supplemented with a different 
concentration of the same drug. The applied drug is screened for its potential to either enhance or suppress a given neurodegeneration phenotype that has been 
caused by targeted genetic manipulation, such as rough eyes caused by mis-expression of human tau, a movement disorder caused by dysfunction of 
Drosophila TDP-43, or reduced lifespan caused by mis-expression of human ASYN. In this way, Drosophila models of neurodegeneration can be used to 
screen compound collections for their potential to prevent or ameliorate a specific neurodegenerative “disease”. (b) Three different concentrations of a drug 
(10 μM, 100 μM, and 1 mM) are chronically applied to ageing Drosophila, as compared to vehicle treated flies. The resulting effects on locomotion are 
quantified using a negative geotaxis assay: flies are shaken to the bottom of a vial/cylinder; their innate behaviour triggers them to move upwards (against 
geotaxis) and the time it takes them to reach the top is scored for a cohort of flies and multiple replicates. A calculus then determines the relative performance 
of these flies exposed to a given drug concentration and at a specific day. The graph shows that the geotaxis performance inversely correlates with drug 
concentration and age, suggesting that this drug enhances a movement disorder in a concentration-dependant and age-related manner. 508      CNS & Neurological Disorders - Drug Targets, 2010, Vol. 9, No. 4  Frank Hirth 
Table 1.  Alzheimer’s Disease-Associated Genes 
 
Gene/Protein  Inheritance  Fly Homolog  Protein Function 
APP AR  Appl/CG7727  Pre-synaptic  
protein 
PSN-1/2 AR  dPs/CG18803  Gamma-secretase  
activity 
Tau unclear  tau/CG31057  Microtubule  
stabilization 
APOe4 unclear  None  Lipid/cholesterol  
metabolism 
APP = amyloid precursor protein; Appl = amyloid precursor protein-like; PSN-1/2 = 
presenilin-1/2; dPS = Drosophila presenilin; APOe4 = apolipoprotein e4; AR = 
autosomal recessive. 
 
APP AND ABETA 
 The  Drosophila homologue of APP, -amyloid protein 
precursor-like (Appl, CG7727), is expressed in the central nervous 
system; however, mutational inactivation of Appl does not cause a 
neurodegenerative phenotype [95]. Flies deleted for the Appl gene 
are viable, fertile, and morphologically normal, yet they exhibit 
subtle behavioural deficits: a fast phototaxis defect can be observed 
which is partially rescued by wild-type, but not mutant APPL. 
There is functional homology between APPL and human APP, as 
transgenes expressing human APP show a similar level of rescue as 
the fly protein. Drosophila APPL lacks homology to APP within 
the Abeta peptide region, and thus is not cleaved like mammalian 
APP, and Abeta deposition does not occur in Drosophila. 
Interestingly, however, a recent report identified a beta-secretase-
like cleavage site in APPL [96], but further proof is required to 
show that this is a functional site leading to Abeta-like deposition. 
Accordingly, Drosophila models of APP-mediated AD have used 
the GAL4/UAS-system to over-express human forms of Abeta. 
  These models recapitulate, at least to some extent, aspects of 
human AD pathology, including Abeta plaque deposition [97, 98], 
defective axonal transport [99, 100] and axonopathies [101], 
mitochondrial mislocalisation [102], defects in synaptic plasticity 
[103] and progressive locomotor deficits [98], affected life-span 
[97, 98, 104], and age-dependent neurodegeneration including 
vacuolization of the brain [97, 98, 105]. The severity of these 
phenotypes is related to Abeta toxicity, with the Abeta 42 arctic 
mutation being the most toxic form. 
 Drosophila Abeta models were subsequently utilised to target 
modifiers of AD pathology by genetic or pharmacological 
interference. Genetic experiments showed that secretase inhibitors 
and neprilysin can ameliorate Abeta42 phenotypes, by either 
reducing Abeta production [67, 104, 106] or by increasing Abeta 
degradation [107, 108]. In addition, a recent study identified 
FKBP52, a prolyl-isomerase of the immunophilin/FK506 binding 
protein family as a modifier of Abeta toxicity. This study also 
showed that mutations in the copper transporter Atox1 which 
interacts with FKBP52 enhance Abeta pathology which can be 
suppressed in FKBP52 mutant flies raised on a copper chelator diet 
[109]. Pharmacological interference identified Congo Red [104] 
and glutaminyl cyclase inhibitors [110] as effective suppressors of 
Abeta deposition and amyloid plaque formation. 
  Resulting from these studies, several signalling pathways have 
been identified as potential mediators of Abeta pathogenesis. These 
include altered Toll->NFkappaB signalling [65], age-dependent 
autophagic-lysosomal injury [111], and the Abelson tyrosine 
kinase/JNK stress kinase cascades [112]. Autophagy and JNK 
signalling have been shown to be altered in human AD [113, 114]. 
However, it is not clear whether these pathways are activated 
because of a causal relationship to disease formation/progression or 
because of a cellular protection attempt. In any case, these studies 
not only corroborate the amyloid cascade hypothesis, but also 
support recent data indicating that Abeta oligomerization, rather 
than plaque formation, is the toxic event that acts as a seed for 
Abeta aggregation [110, 115, 116]. Yet, it is unknown how Abeta 
oligomerization causes neuronal cell death. 
PRESENILIN AND FAD 
  FAD mutations in PS1 and PS2 alter proteolytic processing of 
APP to generate more toxic Abeta42 peptides which accelerates 
amyloid plaque formation in brain tissues. PS mutations also 
contribute to neurodegeneration and cognitive decline through 
amyloid-independent mechanisms, involving altered regulation of 
receptor signalling and intracellular kinase activity. Drosophila 
Presenilin ( Psn, CG18803) represents the only fly homologue of 
the mammalian PSN1 and PSN2 genes. Functional studies in 
Drosophila showed that it is involved in various biological 
processes: cytoskeleton organization and biogenesis; cell fate 
commitment; nervous system development; Notch receptor 
processing; membrane protein ectodomain proteolysis; cell-cell 
adhesion and intracellular signalling cascades. With regard to 
neurodegeneration,  Drosophila Psn is not involved in Abeta42 
production because APPL lacks homology to APP within the Abeta 
peptide region, and thus is not cleaved like mammalian APP. 
Accordingly, a more suitable substrate to monitor Psn FAD mutant 
activity in Drosophila is the Notch receptor, the most extensively 
characterized fly gamma-secretase substrate [117]. Psn is required 
throughout  Drosophila development for Notch signalling, and a 
wide variety of Notch-related phenotypes exist that range from 
severe embryonic lethality to specific defects in adult tissues [118]. 
  As is the case for Abeta models, Psn1/2 wild-type and mutant 
forms have been mis-expressed in Drosophila. These studies reveal 
that PSN FAD mutant activities are tightly linked to the age-of-
onset of degeneration, suggesting that disease severity primarily 
reflects differences in PSN mutant lesions [119]. Most recent 
studies relate PSN-mediated pathogenesis to ubiquilin dysfunction 
[120, 121] and defective calcium storage that can be suppressed by 
calmodulin loss-of-function mutations [122]. The latter model 
underscores earlier findings suggesting that perturbed neuronal Ca
2+ 
homeostasis is implicated in PSN and APP-mediated AD 
pathogenesis, whereby the resulting toxic forms of Abeta can 
induce Ca
2+ influx into neurons. This occurs by Abeta forming an 
oligomeric pore in the membrane which in turn renders neurons 
vulnerable to excitotoxicity and apoptosis (for review see [123]). 
However, as is the case for Abeta models, the actual cause(s) of cell 
death are currently unknown, although defects in axonal transport 
and synaptic dysfunction refer to cytoskeletal abnormalities that are 
the major culprit of AD-related tauopathy. 
TAU AND TAUOPATHY 
  Pathological aggregation of the microtubule-associated protein 
tau [124] is a defining feature not only of AD but also of other 
neurodegenerative diseases collectively called tauopathies [91, 92, 
125]. The process of tau accumulation, paired helical filament 
assembly, and aggregation is incompletely understood. While tau 
hyper-phosphorylation clearly accelerates neurodegeneration, the 
role of other posttranslational modifications, including proteolysis, 
ubiquitination, nitration, and glycosylation, as well as the function 
of the tau amino terminus in this process, remain unclear. 
 The  Drosophila homologue of MAPtau, tau (CG31057) exhibits 
46% identity and 66% similarity with the human protein. However, 
the fly protein does not contain the N-terminal repeats found in 
several human isoforms of tau [126]. To date, Drosophila models of 
tauopathy rely on the over-expression of wild-type or mutant forms of 
human tau, including the FTD-related P301L, V337M and R406W 
mutants. The resulting phenotypes mimic, at least to some extent, the Drosophila melanogaster in the Study of Human Neurodegeneration  CNS & Neurological Disorders - Drug Targets, 2010, Vol. 9, No. 4     509 
human disease condition, including learning and memory deficits 
[127], phosphorylation–dependent tau toxicity [128, 129], correlation 
between FTD-related mutant forms and enhanced toxicity [130, 131], 
tangle formation in some [132] but not all cases [see, f.e. 130], 
synergistic interaction with Abeta leading to Hirano body formation 
[131], and altered life-span as well as region-specific 
neurodegeneration in the adult brain [130-132]. 
  Subsequent genetic interaction studies showed that kinase-
dependent phosphorylation increases tau toxicity and identified 
Shaggy/glycogen synthase kinase-3 [132] and MARK/Par-1 [129, 
133] as key players in this process. In addition, genetic modifier 
screens identified targets and signalling pathways as potential 
mediators of tau toxicity, including puromycin-sensitive 
aminopeptidase [134], altered Wingless [132] and JNK [135] 
signalling, as well as TOR-mediated cell cycle activation [136]. 
Although it is still unclear whether aberrant cell cycle activation is 
directly causing tauopathy/neurodegeneration (see, for example, 
[137]), a potential role of defective TOR signalling has been further 
substantiated by pharmacological interference. These data show 
that rapamycin targeting TOR is able to reduce wild-type or mutant 
tau-induced toxicity by reducing insoluble tau [138]. Yet, the 
relevance of puromycin-sensitive aminopeptidase and TOR 
signalling in human AD pathogenesis remains to be established. In 
contrast, pathological tau phosphorylation has been shown to be 
involved in human disease progression [139], and there is at least 
circumstantial evidence that altered JNK signalling may contribute 
to AD formation and/or progression [114]. 
PARKINSON’S DISEASE 
  Parkinson’s disease is the most common neurodegenerative 
movement disorder characterized by severe motor symptoms, 
including uncontrollable tremor, imbalance, slowness of movement 
and rigidity. Among the exemplary pathological changes observed 
in PD is the progressive loss of dopamine (DA) neurons in the 
substantia nigra pars compacta of the ventral midbrain, although 
neuropathology is not limited to this region [89]. DA neurons of the 
substantia nigra pars compacta innervate the putamen and caudate 
via  the nigrostriatal pathway and thereby exert a stimulating 
function to the striatum regulating motor control. Loss of DA 
neurons and the subsequent degeneration of the nigrostriatal 
pathway are a primary cause for movement disorders observed in 
PD cases. DA cell loss is usually associated with the presence of 
intraneuronal inclusions known as Lewy bodies, which are 
composed principally of ASYN [9]. 
  PD prevalence increases with age, with a mean age of onset 
around 70 years, although 4% of patients develop early-onset 
disease before the age of 50 [140]. The mean disease duration from 
diagnosis to death is 15 years, but the precise mode of death is often 
difficult to determine. Males appear to be 1.5 times more likely to 
develop PD than females, although the underlying causes are not 
known [141]. PD is progressive and current treatment is 
symptomatic only with DA (levodopa) replacement as the major 
therapy. The majority of PD cases are sporadic, likely to be caused 
by a combination of risk factors, the most evident being age. 
However, there are also rare familial disease forms caused by gene 
mutations which show similar clinical and neuropathological 
features. Although these inherited forms account for 5% of all PD 
cases only, studies of the function of the affected genes have 
provided insights into PD pathogenesis. 
  Several genetic loci have been identified that are affected in 
familial forms of PD or have been identified as being associated  
with PD. These include (see Table 2):  alpha-synuclein (asyn), 
parkin,  ubiquitin carboxy-terminal hydrolase L1 ( UCHL1), 
phosphatase and tensin homologue (PTEN)-induced kinase 1, 
(PINK1),  DJ-1,  leucine-rich-repeat kinase 2 ( LRRK2),  high 
temperature requirement protein A2 (HTRA2), glucocerebrosidase, 
polymerase gamma and tau [141-146]. Based on pathophysiology 
as well as genetic defects, three types of cellular dysfunction are 
currently implicated in the pathogenesis of PD: abnormal protein 
aggregation, oxidative damage, and mitochondrial dysfunction 
[142, 143, 145, 147, 148]. Homologues for PD genes exist in 
Drosophila, with the interesting exception of ASYN (see Table 2). 
Accordingly, Drosophila models of PD have been established based 
on the experimental approaches outlined above. Rather than listing 
them gene by gene, I consider it more reasonable to summarise the 
prerequisites, main findings and resulting insights into PD 
pathogenesis. 
PARKINSONISM IN DROSOPHILA 
  Synthesis of the neurotransmitter DA is conserved between 
Drosophila and human and distinct clusters of DA neurons are 
detectable in the developing and adult fly brain [149]. Comparable 
to the human condition, the Drosophila DA system is also involved 
in locomotor control [150, 151], although the details of the 
underlying neural circuit(s) are unknown. It is therefore reasonable 
to assume that loss of DA neurons can affect locomotion in 
Drosophila  comparable to the situation in PD. Indeed, loss of 
subsets of DA neurons in the brain as well as locomotion defects 
are the two principal parkinsonian-like phenotypes used to 
Table 2.  Parkinson’s Disease-Associated Genes 
 
Gene/Protein  Inheritance  Fly Homolog  Protein Function 
Alpha-synuclein AD  None  Pre-synaptic  protein 
Parkin  AR  parkin/CG10523  E3 ubiquitin ligase 
UCH-L1  unclear  Uch/CG4265  E3 ubiquitin hydrolase/ligase 
PINK1 AR  Pink1/CG4523  Mitochondrial  kinase 
DJ-1 AR  DJ-1a/CG6646  
DJ-1b/CG1349 
Redox sensor/Chaperone 
LRRK2 AD  lrrk2/CG5483  Kinase/GTPase 
HtrA2  AD  HtrA2/CG8486  Mitochondrial pro-apoptotic protease 
GBA unclear  CG33090  Lysosomal  enzyme 
POLG unclear  tamas/CG8987  Mitochondrial  DNA polymerase  
Tau unclear  tau/CG31057  Microtubule  stabilisation 
UCH-L1 = ubiquitin carboxyl-terminal esterase L1; PINK1 = PTEN induced putative kinase 1; LRRK2 = leucine-rich repeat kinase 2; HtrA2 = high temperature requirement protein 
A2; glucocerebrosidase = GBA; POLG = polymerase gamma; AD = autosomal dominant; AR = autosomal recessive. 510      CNS & Neurological Disorders - Drug Targets, 2010, Vol. 9, No. 4  Frank Hirth 
characterise fly models of PD. Both phenotypes have been induced 
by mis-expression of wild-type and/or mutant forms of human PD 
genes, including ASYN [152-160], PINK1 [159, 161, 162], Parkin 
[154-156, 163, 164] and LRRK2 [165-169]. 
  Loss-of-function mutations or DA neuron-specific inactivation 
of the respective Drosophila homologues of PINK1 [161, 170-173], 
Parkin [61, 174-176], DJ-1 [69, 177-182], LRRK2 [165, 166, 173, 
183], and HtrA2 [184-186] can also lead to parkinsonism-like DA 
cell loss and locomotor defects. However, it should be noted that in 
several cases loss of the Drosophila homologue of a human PD 
gene causes a much weaker phenotype than mis-expression of the 
corresponding human protein. Moreover, for some models 
including LRRK2 and HtrA2 there are conflicting data as to 
whether loss of the Drosophila homologue causes a parkinsonian-
like phenotype or not [166, 183, 185, 186]. These discrepancies 
might be attributable, at least to some extent, to the inherent 
artificial situation of Gal4-mediated protein overload added to the 
endogenous protein level. In addition, the total number of DA 
neurons per cluster varies between individual wild-type flies [White 
and Hirth, unpublished] and the methods used to measure DA cell 
loss can substantially impact on the phenotypic read-out [187]. 
  In addition to these genetic modifications, pharmacological 
insults also cause parkinsonian-like phenotypes in Drosophila, 
thereby modelling sporadic cases of PD. The pesticide rotenone as 
well as paraquat-induced oxidative damage cause cluster-specific 
DA neuron loss together with motor deficits that can be ameliorated 
by levodopa added to the food [188, 189]. In contrast, a Drosophila 
model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced 
parkinsonism [for review see 142] has not been established so far. 
  It should be noted, however, that in Drosophila the majority 
of these genetic and pharmacological models do not reveal Lewy 
body formation, which is a predominant pathological feature of 
both familial and sporadic cases of PD. As noted above, a 
Drosophila homologue of ASYN is missing which may account for 
the lack of Lewy body formation, except for those cases where 
human ASYN is mis-expressed in the fly [152, 153, 157, 160, 190]. 
Nevertheless,  Drosophila models of PD have revealed valuable   
insights into potential pathogenic mechanisms and identified targets 
of ASYN and other PD-related genes. 
MECHANISMS AND TARGETS OF PARKINSONISM 
  ASYN is the principal component of Lewy bodies found in the 
majority of PD cases and therefore represents a prime target for PD 
research. Although a role in synapse homeostasis is suggested, its 
wild-type function remains elusive [191]. Insights into ASYN-
mediated pathogenesis come from studies showing that 
phosphorylation and enhanced oligomer formation are the major 
culprits of ASYN toxicity in Drosophila [157, 190-193]. Thus, 
phosphorylation at residue serine 129 can ameliorate [190] whereas 
phospho tyrosine 125 can exacerbate soluble oligomer formation 
and toxicity [193]. Moreover, a recent elegant study addressing the 
in vivo impact of biophysically defined pre-fibrillar variants of 
ASYN showed that the increasing potential to form fibrils and 
soluble oligomers correlates with increasing neurodegeneration, not 
only in Drosophila but also in C. elegans and human cell culture 
models [192]. These data suggest that soluble oligomers are the 
most toxic species in PD-like pathogenesis, which is further 
supported by the fact that an ASYN mutant lacking residues 71-82 
and unable to form oligomers and fibrils, is also unable to induce 
DA neurotoxicity in the fly [157]. 
 Drosophila ASYN models have been used to target modifiers 
of PD pathology by genetic or pharmacological interference. 
Genetic experiments showed that calpain cleavage [194] and 
superoxide dismutase (SOD) activity [158] affect ASYN, whereas 
inhibition of Silent information regulator 2 (Sir2), a nicotinamide 
adenine
 dinucleotide–dependent histone deacetylase rescues ASYN 
toxicity [66]. Moreover, ASYN inhibits histone acetylases and its 
neurotoxic effects can be rescued by histone deacetylase inhibitors 
[195], further supporting a link between ASYN-mediated 
pathogenesis and histone acetylation. Pharmacological interference 
identified nicotinamide which can improve motor deficits [196]; as 
does dietary supplementation of S-methyl-L-cysteine, a substrate in 
the catalytic antioxidant system mediated by methionine sulfoxide 
reductases [197]. In addition, geldanamycin can suppress ASYN 
toxicity, a process that appears to be mediated by heat shock protein 
70 chaperone activity [68]. 
  The latter studies strongly suggest that ASYN-mediated 
pathogenesis is accompanied, if not accelerated by a stress 
response, which can be also found in other Drosophila models of 
PD. Loss of PINK1 function in the fly eye can be suppressed by 
SOD1 as well as with vitamine E [161]. Loss of parkin leads to 
oxidative stress [175] and in both ASYN and parkin models, 
neuronal cell loss can be overcome by genetic or pharmacological 
interventions increasing glutathione synthesis or glutathione 
conjugation activity [198]. This detox activity of parkin might be 
mediated by glutathione S-transferase S1 [61]. Parkin also 
associates with parkin-associated endothelin receptor-like receptor, 
which by itself can cause parkinsonism in Drosophila [154, 199]. 
Similar to ASYN and parkin, DJ-1 has been shown to be involved 
in an oxidative stress response [69, 177-179, 181, 182]. Some of 
these screens also indentified signalling pathways that mediate PD-
like pathogenesis. Among those involved in Parkin-mediated 
pathogenesis are PI3K/Akt [180, 200], JNK [176] as well as TOR 
signalling [167, 173]. Interestingly, both Parkin and LRRK2-
mediated pathogenesis can be ameliorated with rapamycin targeting 
4E-BP activity [173], a situation comparable to its application in 
Drosophila models of tauopathy [138]. 
PD-RELATED MITOCHONDRIAL DYSFUNCTION 
  A surprising and equally promising finding of these interaction 
studies in Drosophila was the discovery that LRRK2, PINK1 and 
Parkin genetically interact with each other [168, 173] as does DJ-1 
[169]. PINK1 is able to phosphorylate Parkin, which is a 
requirement for its mitochondrial localisation [201]. PINK1 and 
Parkin loss-of-function genotypes phenocopy each other as both 
affect mitochondrial morphology. Subsequent epistatic analyses 
demonstrated that the mitochondrial phenotype caused by PINK1 
loss-of-function can be rescued by Parkin [170-172]. Moreover, 
over-expression of human Parkin mutant R275W but not wild-type 
or G328E mutant can cause mitochondrial abnormalities similar to 
Parkin loss-of-function mutants [163]. These data strongly suggest 
that at least PINK1 and Parkin act together in a common pathway 
regulating mitochondrial function [57, 58]. 
  Mitochondria are endosymbiontic organelles found in all 
eukaryotic cells required for ATP production as well calcium 
buffering and apoptotic signals [202]; they encode their own DNA 
(mtDNA) in up to 1000 copies per cell, and undergo frequent 
morphological changes through fission and fusion, thereby 
retaining mtDNA integrity and essential neuronal function, such as 
synaptic transmission, plasticity, and ultimately cell survival [203, 
204]. The PD model studies in Drosophila showed that PINK1 and 
Parkin regulate mitochondrial morphology [162, 205, 206], 
potentially by acting on Drp-1 [207] and other factors mediating 
mitochondrial fission/fusion. It should be noted, however, that the 
majority of these interactions have been discovered and described 
using the fly muscle as a model, and not in DA neurons of the fly 
brain itself. Moreover, it is currently not known whether PINK1 
and/or Parkin act directly or indirectly on genes regulating 
fission/fusion and mtDNA integrity. PINK1 and Parkin loss-of 
function increases Drp-1 dependent mitochondrial fragmentation, 
suggesting that at least a feedback loop exists between 
PINK1/Parkin signalling and mitochondrial fission/fusion. It 
remains to be shown whether this feedback loop requires other 
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  In summary, these examples of Drosophila research into human 
PD corroborate and extend current hypotheses suggesting that 
abnormal protein aggregation, oxidative damage and mitochondrial 
dysfunction are causally related to PD pathogenesis. The results 
obtained in Drosophila led to the identification of homologues and 
homologous pathways involved in the formation and progression of 
parkinsonism. Thus, despite some heterogeneity, these models 
identify oligomer formation of ASYN and histone acetylation, as 
well as altered PINK1/Parkin signalling and mitochondrial 
dysfunction as two distinguishable pathogenic pathways underlying 
PD-like neurodegeneration – a situation corresponding to the 
human disease condition [145]. These data from Drosophila also 
identify JNK as well as PI3K/Akt and TOR signalling as 
contributors to disease progression, whereas detox pathways 
reducing oxidative stress, either genetically or pharmacologically, 
can ameliorate it. Significantly, these pathways parallel some of 
those involved in AD pathogenesis, indicating that common disease 
mechanisms may underlie AD and PD-like neurodegeneration. 
TRINUCLEOTIDE REPEAT EXPANSION DISEASES 
  TREDs account for more than 16 neurological disorders that are 
caused by aberrant expansion of triplet reiterations in either coding 
or non-coding regions of disease-specific genetic loci that result in 
dysfunction of the respective protein, eventually leading to 
neurodegeneration and, ultimately, patient death (for review see 
[208]). The majority of TREDs are diseases caused by expansion of 
CAG repeats coding for glutamine (polyglutamine, PolyQ), 
including HD, spinal bulbar muscular atrophy (SBMA, also 
Kennedy disease), spinocerebellar ataxias (SCA) 1, 2, 3 (also 
known as Machado-Joseph disease), 6, 7, and 17, and 
dentatorubral-pallidoluysian atrophy (DRPLA). Other TREDs 
include Fragile X syndrome (FRX, CGGn repeats) and Friedreich’s 
ataxia (FRDA, GAAn repeats). Apart from codon reiteration as a 
common denominator, TREDs differ in disease-related length of 
expanded repeats, age of onset, clinical features and 
neuropathology. The reader is referred to reviews addressing each 
TRED in more detail [208-210] The genetic loci affected by the 
expansion of unstable trinucleotide repeats have been identified and 
with the exception of the androgen receptor, there is a fly 
homologue known for each of them (see Table 3), which in turn led 
to the establishment of Drosophila models of PolyQ diseases, FRX 
and FRDA. 
POLYQ-RELATED NEURODEGENERATION 
  HD, SBMA, SCA1/2/3/6/7/17 and DRPLA are predominantly 
inherited diseases where polyQ expansions confer structural 
changes to the disease-related protein, leading to oligomeric species 
and protofibril forms rich in beta-sheets [211]. The resulting mutant 
proteins become dominantly toxic and can lead to intra-nuclear 
inclusions in neurons and glial cells, ultimately causing neuronal 
dysfunction and cellular degeneration. The direct causes of 
degenerative cell death still remain elusive but there is an inverse 
correlation between repeat length and disease severity, with 
expansions of 40 glutamines and more being a general threshold for 
disease formation [212]. 
  As is the case for AD and PD, fly models have been generated 
by mis-expression of mutant forms of human polyQ genes as well 
as loss- and gain-of-function of Drosophila homologues. In all of 
these cases, Gal4 specific mis-expression can cause pronounced 
neurodegenerative phenotypes in the eye or central nervous system 
that can be accompanied by aggregated formation and reduced life-
span [for recent review, see 82, 208, 213]. Several studies 
established that toxicity is due to polyQ tracts [214, 215]. However, 
the protein context around the pathogenic expansion strongly 
modulates dominant toxicity, suggesting that the resulting aberrant 
protein conformation may trigger an amyloid-like cascade [216-
218], and that protein-protein interactions are a major culprit of 
polyQ-related neurodegeneration. These protein-protein interactions 
occur even between polyQ-related disease proteins, at least for 
some of the proteins involved in SCA, thereby promoting 
neurodegeneration. For example, nuclear accumulation of ataxin-2 
contributes to SCA1-related neurodegenerative phenotypes caused 
by ataxin-1[82Q], probably by direct interaction [219]. Ataxin-2 
can also modify SCA3-induced neurodegeneration by accelerating 
the onset of nuclear inclusion formation associated with SCA3. 
Ataxin-2 activity depends on a conserved protein interaction 
domain, the PAM2 motif, which mediates binding of cytoplasmic 
poly(A)-binding protein which itself can influence SCA3-
associated neurodegeneration [220]. 
  Based on available fly models of polyQ-induced neurode-
generation, numerous genetic and pharmacological modifier screens 
identified targets affecting protein folding and oligomerization 
[221-228], as well as RNA [229], microRNA [230] and RNA 
processing [228] as mediators of polyQ toxicity. These data suggest 
that altered protein conformation is only one of the causes 
underlying polyQ-induced neurodegeneration. However, the actual 
cause(s) of cell death are currently unknown. Apoptotic signalling 
[228, 231] has been involved, as well as the retinoblastoma 
pathway [232]; sumoylation and ubiquitination [233, 234], as well 
as PI3K/Akt [235] and TOR signalling affecting macroautophagy 
[236]. It is not clear whether these pathways are activated as a cause 
or consequence, but they do provide a target for therapeutic 
intervention. This is particularly evident for histone deacetylase 
(HDAC) inhibitors, which protect against polyQ toxicity [237, 
238]. Interestingly, this effect can be modulated by simultaneous 
Table 3.  Trinucleotide Repeat Expansion Disease-Associated Genes 
 
TRED  Gene/Protein  Inheritance  Fly Homolog  Protein Function 
HD HTT AD  htt/CG9995  Microtubule  binding,  transport 
SCA ATXN1/2/3/7  AD  Atx-1/CG4547  
Atx2/CG5166 
unknown 
SCA17 TBP  AD  Tbp/CG9874  Transcriptional  regulation 
SBMA AR  AD  None  Nuclear  receptor 
DRPLA ATN1  AD  Gug/CG6964  Transcriptional  regulation 
FRX  FMR1/2  X and AD  dFMR1/CG6203  RNA regulation 
FRDA FXN  AR  fh/CG8971  Mitochondrial  protein 
TRED = trinucleotide repeat expansion disease; HD = Huntington’s disease; SBMA = spinal bulbar muscular atrophy; SCA = spinocerebellar ataxias; DRPLA = 
dentatorubropallidoluysian atrophy; FRX = fragile X syndrome; FRDA = Friedreich’s ataxia; HTT = Huntingtin; ATXN-1/2/3/7 = ataxin-1/2/3/7; AR = androgen receptor; TBP = 
TATA box binding protein; CACNA1A = calcium channel, voltage-dependent, P/Q type, alpha 1A subunit; ATN1 = atrophin -1; Gug = Grunge; FMR1/2 = fragile X mental 
retardation 1; FXN = frataxin; fh = frataxin homolog; AD = autosomal dominant; X = X-linked chromosomal segregation; AR = autosomal recessive. 512      CNS & Neurological Disorders - Drug Targets, 2010, Vol. 9, No. 4  Frank Hirth 
inhibition of two HDACs leading to enhanced neuroprotection 
[239], suggesting that HDACs may propagate/accelerate toxicity in 
Drosophila models of PolyQ-mediated neurodegeneration. 
FRAGILE X SYNDROME AND FRIEDREICH ATAXIA 
  Trinucleotide repeat expansion can also occur in non-coding 
regions, as is the case for FRX and FRDA. In both cases, single 
gene loci are affected and repeat expansion of >200 inversely 
correlates with age of onset. FRX occurs in 1/4000 males and 
1/8000 females, leading to mental retardation and behavioural 
abnormalities due to expansion of unstable non-coding CGG 
repeats in the 5 prime untranslated region of fragile X mental 
retardation 1 ( FMR1). These excess repeats cause aberrant 
methylation of CpG islands and decreased histone acetylation in the 
5 prime regulatory region of FMR1, leading to loss of FMR1 and its 
encoded protein FMRP. FMRP is a selective RNA-binding protein 
that shuttles between nucleus and cytoplasm and controls local 
protein synthesis by suppressing mRNA translation (for review see 
[208]). This function of FMRP appears to be evolutionary 
conserved, as both mammalian FMRP and its Drosophila 
homologue  dfmr1 target the microtubule-associated protein 
1B/Drosophila futsch [240]. Local regulation of protein synthesis is 
an essential function in synaptic terminals, and several studies in 
Drosophila identified related targets of dfmr1, including rac1, pick 
pocket [241, 242], discs overgrown and polyA-binding protein 
[243], all of which are implicated in synaptic function. Moreover, 
several loss- and gain-of-function studies demonstrated that dfmr1 
regulates synaptic structure [244] by associating physically and 
functionally with the microRNA pathway, thereby regulating the 
translation of synaptic mRNAs [for review see 245]. 
  FRDA is an autosomal recessive disorder that occurs in 
1/50,000 individuals characterised by gait ataxia due to progressive 
atrophy of dorsal columns, and spinocerebellar and corticospinal 
tracts. Unstable GAA repeats in the first intron of FRDA encoding 
frataxin inhibit transcriptional elongation, leading to decreased 
protein levels. Frataxin localises to the inner mitochondrial 
membrane and is involved in the regulation of iron levels and free 
radical protection. Similar functions have been identified for the 
only  Drosophila homologue, dfh [246-248], suggesting that 
oxidative stress and impaired biosynthesis of Fe-S cluster 
containing proteins in the mitochondrial respiratory chain might be 
causally related to disease. However, as is the case for PD, it is still 
unclear whether and how oxidative stress can cause cell death, or 
whether it is merely a potentiator of mitochondrial dysfunction, 
ultimately leading to neurodegeneration. The available Drosophila 
model of FRDA will certainly allow rigorous testing of several 
hypotheses, including the possibility that impaired oxidative 
phosphorylation due to frataxin deficiency might be the major 
culprit underlying FRDA pathogenesis. 
MOTOR NEURON DISEASES 
  MND is a common denominator for several etiologically 
heterogeneous diseases affecting upper motor neurons located 
principally in the primary motor cortex and/or lower motor neurons 
located in the anterior horn of the spinal cord and the brainstem. 
MNDs include amyotrophic lateral sclerosis (ALS), some forms of 
FTD and fronto-temporal lobar degeneration (FTLD), as well as 
spinal muscular atrophy (SMA), hereditary spastic paraplegia 
(HSP), and others [249-254]. The most prevalent cases are SMA 
(1/6,000-10,000), HSP (3-10/100,000), and ALS (4-6/100,000). 
MNDs vary in severity and can affect all ages from infancy (SMA) 
to late onset (FTD and FTLD). However, in every case, the 
degeneration of motor neurons causes neuronal dysfunction and 
muscle wasting, leading to various locomotor disabilities, such as 
inability to use arms and/or legs, to speak or to swallow, and 
ultimately can cause the death of the patient when breathing 
muscles become involved. 
  To date, there is no effective therapy or cure for MND. As is 
the case for AD and PD, the majority of MND cases are sporadic 
and the causes are unknown. However, the identification of protein 
aggregates (fragmented, phosphorylated, ubiquitinated) in 
intracellular inclusions as well as the analyses of heritable, familial 
cases led to the identification of genes involved in MND 
pathogenesis (Table 4). In some cases motor neuron death is caused 
by mutations in a single gene, such as survival of motor neurons 
(SMN) causing SMA [255]. For the majority of these disease-
related genes, Drosophila homologues are present (Table 4) and 
movement disorders can be easily monitored in the fly (Fig. 4). 
Thus, loss- and gain-of-function analyses or mis-expression of the 
human disease gene have been used to establish fly models of 
MND. 
AMYOTROPHIC LATERAL SCLEROSIS 
  ALS is the most common adult-onset MND affecting upper and 
lower motor neurons, with an age of onset between 40 and 60 years. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Experimental study of Drosophila locomotor behaviour. (a) An adult wild-type fly (wt, arrow) is kept in an arena which can be a converted petri 
dish. The fly’s activity and movement is recorded with a high-speed video camera and a computer programme tracks the resulting trajectory during a given 
time-window (30sec). (b) 3min movement trajectory of a wt fly; (c) 3min trajectory of a mutant fly (ko) revealing motor deficits. Video-assisted movement 
tracking records locomotor behaviour and in turn allows the quantification of parameters that can be used to describe it, including walking activity, velocity, 
and distance travelled. By applying this method to Drosophila models of neurodegeneration, it is possible to mimic adult-onset neurodegenerative movement 
disorders including Parkinson’s disease, trinucleotide repeat expansion diseases, and motor neuron diseases, and to monitor their effect on neural circuits and 
behaviour, which in turn allows genetic dissection of the underlying pathogenic mechanism(s). Drosophila melanogaster in the Study of Human Neurodegeneration  CNS & Neurological Disorders - Drug Targets, 2010, Vol. 9, No. 4     513 
The majority of ALS cases are sporadic with currently unknown 
causes whereas 5-10% are familial cases (FALS), for which several 
disease-related genes have been identified [253, 254]. Most 
prominent among them are mutations of the Cu/Zn superoxide 
dismutase SOD1 which account for 15-20% of autosomal dominant 
FALS cases and 1-2% of all ALS cases. Although implicated in 
anti-oxidative activity, the precise role of SOD1 dysfunction in 
ALS is incompletely understood [256]. Drosophila models of 
SOD1 include mis-expression of human FALS forms as well as 
loss-and gain-of-function of the Drosophila SOD1 homologue 
[257-261]. 
  Surprisingly and in contrast to the human condition, initial 
studies in Drosophila showed that expression of either Drosophila 
or human SOD1 results in increased lifespan without affecting 
locomotion or motor neuron survival [258-260], whereas loss of 
Drosophila SOD1 decreases lifespan [260] and causes necrotic cell 
death in the fly eye [257]. Yet, a recent study suggests that motor 
neuron-specific expression of wild-type or disease-linked (A4V, 
G85R) mutants of human SOD1 do not affect lifespan but induce 
progressive climbing defects that are accompanied by impaired 
neural circuit physiology and a stress response in surrounding glial 
cells [261]. The observed phenotypes occurred without loss of 
motor neurons but were accompanied with an age-related 
accumulation of mutant human SOD1-specific aggregates. These 
data, together with earlier results [257] raise the interesting 
possibility that SOD1 mutations leading to soluble oligomers rather 
than aggregate formation confer cellular toxicity – as seen for 
Abeta in AD and for ASYN in PD. 
  In addition to SOD1, TDP-43 was recently identified as a major 
player in the pathogenesis of ALS and probably other 
neurodegenerative diseases. TDP-43 encodes a primarily nuclear 
protein with so far unknown function(s) in the nervous system 
[262]. Phosphorylated and ubiquitinated C-terminal fragments of 
TDP-43 are found as cytoplasmic inclusions not only in ALS and 
FTLD [15, 16], but also in AD and PD [263]. Significantly, TDP-43 
mutations affecting the C-terminal part of the protein have been 
found in both sporadic ALS and FALS (for review, see [264]), 
suggesting that cytoplasmic accumulation and/or nuclear loss-of-
function of TDP-43 is causally related to MND formation. 
Drosophila encodes two homologues of TDP-43 (Table 4) and 
three recent publications provide initial insights into the function of 
one of these homologues [265-267]. Two of these studies show that 
hypomorhpic TBPH alleles lead to reduced lifespan and locomotor 
defects [265,266]. As potential causes, changes in the number of 
synapses at the larval neuromuscular junction (NMJ) [265] and 
defective dendritic pruning of larval sensory neurons [266] are 
reported. A third study describes a TBPH deletion which causes 
larval lethality accompanied by reduced HDAC6 levels, a 
molecular phenotype also seen in HEK293E cells depleted for 
TDP-43 [267]. In addition, a recent study over-expressed human 
forms of wild-type and mutant TDP-43 that where C-terminally 
tagged with red fluorescent protein (RFP). Mis-expression of these 
constructs led to degenerative phenotypes in the eye and central 
brain [268], but it remains to be seen whether these phenotypes are 
attributable to gain of TDP-43 function or rather to RFP. Moreover, 
insights into tissue-specific gene expression or potential pathogenic 
mechanisms underlying TDP-43-related adult-onset, age-related 
MND are still lacking. 
  Fly models of ALS also exist for vesicle-associated membrane 
protein B (VAPB) which is involved in rare cases of late-onset 
ALS. The VAPB P56S mutation is nevertheless of interest because 
it was found in ALS and SMA cases, indicating a potential common 
pathogenic mechanism underlying both MNDs. Mis-expression of 
wild-type or mutant forms of human VAPB as well as loss-of-
function of the corresponding Drosophila homologue VAP33-1 
[269, 270] affect synapse formation and maintenance [269-271] and 
can lead to aggregate formation, motor neuron loss and locomotion 
defects. The underlying pathogenic mechanisms are only beginning 
to emerge. A recent study suggests that VAP33/VAPB leads to 
defective bone morphogenetic protein (BMP) signalling at the 
NMJ, eventually causing motor neurodegeneration [270], whereas 
another study demonstrated that VAPB is involved in Eph receptor 
signalling [272]. 
SPINAL MUSCULAR ATROPHY 
  SMA is, after cystic fibrosis, the most common autosomal 
recessive disorder in humans and is characterised by loss of lower 
motor neurons and progressive muscular atrophy in the limbs and 
trunk, eventually leading to respiratory failure and death [250]. 
SMA is caused by recessive mutations of SMN1 which, together 
with  SMN2 provides functional SMN required for motor neuron 
survival. Disease severity is inversely proportional to levels of 
Table 4.  Motor Neuron Disease-Associated Genes 
 
MND  Gene/Protein  Inheritance  Fly Homolog  Protein Function 
ALS SOD1  AD/(AR)  Sod/CG11793  Superoxide  dismutase 
ALS Alsin  AR  CG7158  unknown 
ALS SETX AD  None DNA/RNA  helicase 
ALS FUS/TLS  AD/(AR)  caz/CG3606  Transcription/RNA  processing 
ALS VAPB AD  Vap-33-1/CG5014  Cargo  transport 
ALS TDP-43 AD  TBPH/CG10327  
CG7804 
Transcription/RNA processing 
ALS CHMP2B  unclear  CG4618  Endosomal  sorting/transport 
SMA SMN-1/2  AR Smn/CG16725  Transcription/RNA  processing 
HSP SPAST AD  dSpast/CG5977  Microtubule  organisation 
HSP  NIPA1  AD  spict/CG12292  Synaptic growth/BMP signalling 
HSP ATL-1 AD atl/CG6668  Membrane  fusion/ER 
MND = motor neuron disease; ALS = amyotrophic lateral sclerosis; SMA = spinal muscular atrophy; HSP = hereditary spastic paraplegia; SOD1 = Cu/Zn superoxide dismutase 1; 
SETX = senataxin; FUS/TLS = fused in sarcoma/translocated in liposarcoma; caz = cabeza; VAPB = vesicle-associated membrane protein B; Vap-33-1 = vesicle-associated 
membrane protein 33-1; TDP-43 = transactive response DNA-binding protein 43; TBPH = transactive response  DNA-binding protein homologue; CHMP2B = charged 
multivesicular body protein 2B; SMN-1/2 = survival of motor neuron protein 1/2; SPAST = spastin; NIPA1 = non-imprinted in Prader-Willi/Angelman syndrome 1; spict = 
spichthyin; ATL-1 = atlastin-1; ER = endoplasmatic reticulum; AD = autosomal dominant; AR = autosomal recessive. 514      CNS & Neurological Disorders - Drug Targets, 2010, Vol. 9, No. 4  Frank Hirth 
SMN; however, the mechanistic details of a motor neuron 
requirement of SMN are incompletely understood [255]. 
Drosophila encodes a homologue of SMN and loss-of-function of 
dSMN results in recessive larval lethality and NMJ defects [273, 
274] which appear to be due to a bidirectional function of dSMN in 
both muscles and neurons [275]. A subsequent genomic screen 
characterised enhancers and suppressors of dSMN and identified 
altered BMP signalling as a potential pathogenic pathway – a 
situation strikingly similar to the ALS-related VAP33/VAPB 
phenotype [270]. 
HEREDITARY SPASTIC PARAPLEGIA 
  HSP describes a heterogeneous group of genetic disorders that 
are characterised by retrograde axonal degeneration of the 
corticospinal tracts and posterior columns in the spinal cord, 
leading to the loss of lower motor neurons and subsequent 
progressive spasticity and weakness of the lower limbs [276]. 
Several genetic loci have been identified that are causally related to 
HSP formation (for a recent update see [254]). The majority of 
cases are caused by mutations in Spastin which account for 40% of 
autosomal dominant HSP [277]. A Drosophila homologue has been 
identified [278] and several studies addressing dSpastin loss-of-
function phenotypes as well as over-expression of human mutant 
forms established a role in microtubule organisation/stability, 
synapse morphology and neurotransmitter release at the NMJ [279-
283]. Insights into the underlying pathogenic pathway(s) are 
coming from studies addressing the function of two other HSP-
related genes, Atlastin-1 (Atl-1) and non-imprinted in Prader-
Willi/Angelman syndrome 1 (NIPA1). 
 Drosophila Atl localizes to endoplasmic reticulum membranes 
and mediates membrane tethering and fusion [284]; it is also 
expressed in muscles and functions with Spastin in microtubule 
organisation/stability [285]. Genetic analyses revealed that 
Drosophila Atl is required for normal growth of muscles and 
synapses at the NMJ as loss-of-function mutations lead to reduced 
muscle size and increased numbers of synaptic boutons. Defects are 
accompanied by altered expression levels of synaptic proteins Dlg 
and alpha-spectrin and can be rescued by muscle but not neuron-
specific Atl expression [285], suggesting that Atl and Spastin 
regulate synapse morphology at the NMJ via  microtubule 
organisation/stability. Loss-and gain-of-function mutations of 
Spichthyin (Spict), the Drosophila homologue of human NIPA1, 
revealed that Spict regulates microtubule maintenance and 
morphology of presynaptic NMJs by way of BMP signalling, where 
it interacts with BMP receptors and promotes their internalization 
from the plasma membrane [286]. A recent follow-up study showed 
that mammalian NIPA1 also interacts with BMP type II receptor 
and similarly inhibits BMP signalling by regulating BMP receptor 
traffic [287]. Moreover, this study also provides evidence that 
spastin and another HSP-related gene spartin are also inhibitors of 
BMP signalling [287], indicating an evolutionary conserved role of 
Spast, Spict/NIPA1 and other HSP-related proteins in the regulation 
of BMP-mediated synapse morphology at the NMJ. 
  It is becoming apparent from these Drosophila studies into 
human MND that mutations of fly homologues of VAPB [270], 
SMN [275], NIPA1 and Spastin [286, 287] all seem to activate the 
same pathogenic pathway, suggesting that de-regulated BMP type 
II receptor signalling may unify ALS, SMA and HSP. This would 
make sense because all three MNDs affect lower motor neurons and 
BMP activity has been shown to play a significant role in the 
development and function of the NMJ [for review see 288, 289]. It 
will be interesting to see whether other MND-related genes also 
impinge on BMP signalling and whether its alteration is a cause or 
consequence of progressive motor neuron degeneration. 
 
 
CONCLUDING REMARKS AND OUTLOOK 
  The above mentioned studies exemplify Drosophila research 
over the past two decades in the study of human neurodegeneration 
which led to the establishment of reliable models for Alzheimer’s, 
Parkinson’s, and motor neuron diseases, as well as models for 
Trinucleotide repeat expansion diseases. These studies made 
valuable contributions to our understanding of the molecular, 
genetic, and cellular aspects of neurodegeneration from genes to 
brain and behaviour. However, three major aspects still remain 
elusive and further efforts are required to address them. 
WHAT CAUSES CELLULAR DEGENERATION? 
  The majority of neurodegenerative diseases are associated with 
the accumulation of misfolded proteins into aggregates that contain 
fibrillar structures. Although still debated, the prevalent hypothesis 
is that aggregates represent a cellular protection mechanism against 
toxic aggregation intermediates, whereas soluble oligomers and 
pre-fibrillar species most probably are the major cause of toxicity 
[115, 290, 291]. Several studies in Drosophila support this 
hypothesis [192, 193, 216, 257, 261]. However, the exact nature of 
the toxic species and how they exert their pathogenic function is 
still unclear. Thus, potential toxic species need to be tested in 
available  Drosophila models (see [192]), followed by unbiased 
genome-wide modifier screens to identify molecular pathways 
executing cellular toxicity. In addition, there is mounting evidence 
suggesting that several of these toxic species, including forms of 
Abeta, Tau, ASYN, and HTT may harbour prion-like features that 
can trigger cell-to-cell transmission [292], thereby acting both as 
seeds of disease formation and propagators of disease progression. 
These features are compatible with permissive templating [293] and 
provide an explanation for the spread of disease from initially local 
foci to major regions of the brain, as seen for example in AD and 
PD [89,90]. Significantly, permissive templating represents an 
experimentally testable hypothesis in the search for additional 
prionogenic proteins [294] that may propagate disease progression. 
It remains to be tested whether cell-to-cell transmission of 
proteinopathies can be modelled in Drosophila, but a combination 
of bioinformatic and genetic modifier screens may provide 
powerful tools for experimental analyses. 
WHAT MEDIATES AGE-RELATED PATHOGENESIS? 
  The vast majority of patients suffering from neurodegenerative 
diseases represent sporadic cases. The post-mortem brain of such 
patients is usually characterised by inclusions composed of 
misfolded but non-mutated proteins where the cause of 
pathogenesis remains elusive. Several risk factors have been 
implicated in disease formation and progression, including 
environmental and genetic risk factor(s), but age remains the 
dominant, overarching one. Yet, almost nothing is known about 
age-related pathogenic mechansims and how they impact on 
neurodegeneration. Obvious suspects are genetic instability, decline 
in protein quality control and mitochondrial dysfunction [202, 203]. 
However, these age-related phenotypes may explain some but not 
all of the sporadic cases observed in neurodegenerative diseases. 
Thus, comparable to the multi-hit hypothesis on cancer [295], one 
has to postulate at least two or more initiating events that trigger 
disease formation in an age-related manner. This seems to be the 
case in Drosophila, where deregulation of two or more conserved 
signalling pathways is seen in models of genetically-induced 
proteinopathies. These include PI3K/Akt and TOR signalling in AD 
and PD, JNK signalling in AD and PD, histone acetylation in PD, 
MNDs and TREDs, as well as BMP signalling in MNDs. It is 
currently not clear whether de-regulated signalling represents   
a cause or consequence of disease, nor is it clear whether   
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non-canonical pathway components are involved. However, the 
available genetic tools make it possible to investigate disease 
formation and progression in an adult onset, age-related manner in 
Drosophila, and to screen for unknown pathway components at a 
systematic genome-wide level (see [228]). This will allow genetic 
dissection of pathogenic pathways related to age as the main risk 
factor and to determine the causative roles of individual pathway 
components. 
WHAT PREVENTS DISEASE FORMATION? 
  An increased life expectancy in developed countries will 
steadily increase the number of individuals suffering from age-
related neurodegenerative diseases. This represents an enormous 
socio-economic burden, and will intensify the demand to identify 
and develop new drugs and compounds that can be used for 
targeted treatment(s) in order to prevent or at least ameliorate 
disease symptoms. As part of these efforts, compounds need to be 
screened and tested in reliable models. Drosophila can make a 
significant contribution in this direction, and several successful 
examples have already shown that pharmacological intervention 
can ameliorate the disease, as demonstrated for example by the first 
description of geldanamycin and chaperone treatment of ASYN 
toxicity [68, 153]. Examples like this can directly guide clinical 
research and the development of novel therapeutic strategies for the 
treatment of these debilitating diseases. Considering previous work 
over the last two decades, it is reasonable to assume that 
Drosophila research will continue to make significant contributions 
in the study of human neurodegeneration. 
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ABBREVIATIONS 
AD =  Alzheimer’s  disease 
ALS  = Amyotrophic lateral sclerosis 
APOe4 =  Apolipoprotein  e4 
APP  =  Amyloid precursor protein 
Appl  =  Amyloid precursor protein-like 
AR =  Androgen  receptor 
ASYN =  Alpha-synuclein 
ATL-1 =  Atlastin-1 
ATP =  Adenosin  tri-phosphate 
ATN1 =  Atrophin  -1 
ATXN-1/2/3/7 = Ataxin-1/2/3/7 
BACE =  Beta-site  APP-cleaving  enzyme 
BMP  =   Bone morphogenetic protein 
CACNA1A  =  Calcium channel, voltage-dependent, P/Q type,  
     alpha 1A subunit 
Caz =  Cabeza 
CHMP2B  =  Charged multivesicular body protein 2B 
CNS  =  Central Nervous System 
DA =    Dopamine 
DNA =  Desoxy  ribonucleic  acid 
DRPLA =  Dentatorubropallidoluysian  Atrophy 
ER =  Endoplasmatic  reticulum 
FAD =  Familial  AD 
FALS =  Familial  ALS 
Fh =  Frataxin  homolog 
FMR1/2  =  Fragile X mental retardation 1 
FRDA =  Friedreich’s  ataxia 
FRX =  Fragile  X  syndrome 
FTD =  Fronto-temporal  dementia 
FTLD =  Fronto-temporal  lobar  degeneration 
FUS/TLS  = Fused in sarcoma/translocated in liposarcoma 
FXN =  Frataxin 
GABA =  Gamma-aminobutyric  acid 
GFP  =  Green Fluorescent Protein 
Gug =  Grunge 
HD =  Huntington’s  disease 
HDAC =  Histone  deacetylase 
HSP  =  Hereditary spastic paraplegia 
Hsp70 =  Heat shock protein 70 
HtrA2  =  High temperature requirement protein A2 
HTT =  Huntingtin 
JNK  =  c-Jun N-terminal kinase 
LRRK2  =  Leucine-rich repeat kinase 2 
MND  =  Motor neuron diseases 
MPTP =  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
mtDNA =  Mitochondrial  DNA 
NIPA1  =  Non-imprinted in Prader-Willi/Angelman  
     syndrome 1 
NMJ =  Neuromuscular  junction 
PD =  Parkinson’s  disease 
PI3K =  Phosphatidylinositol  3-kinase 
PINK1  =  Phosphatase and tensin homologue (PTEN)- 
     induced kinase 1 
POLG =  Polymerase  gamma 
PolyQ =  Polyglutamine 
PSN-1/2 =  Presenilin-1/2 
RFP  =  Red Fluorescent Protein 
RNA =  Ribonucleic  Acid 
SBMA  =  Spinal Bulbar Muscular Atrophy 
SCA =  Spinocerebellar  ataxias 
SETX =  Senataxin 
SMA =  Spinal  muscular  atrophy 
SMN-1/2  =  Survival of motor neuron protein 1/2 
SOD1  =  Cu/Zn superoxide dismutase 1 
SPAST =  Spastin 
Spict =  Spichthyin 
TBP  =  TATA box binding protein 
TBPH  =  Transactive response DNA-binding protein  
     homologue 
TDP-43  =  TAR DNA binding protein 43 
TOR  =  Target of rapamycin 
TRED  = Trinucleotide repeat expansion diseases 
UAS  = Upstream activating sequence 
Vap-33-1  =  Vesicle-associated membrane protein 33-1 
VAPB  =  Vesicle-associated membrane protein B 
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